Oral fluoroquinolone use and serious arrhythmia: Bi-national cohort study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Oral fluoroquinolone use and serious arrhythmia : Bi-national cohort study. / Inghammar, Malin; Svanström, Henrik; Melbye, Mads; Pasternak, Björn; Hviid, Anders.
In: BMJ (Online), Vol. 352, i843, 26.02.2016.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Oral fluoroquinolone use and serious arrhythmia
T2 - Bi-national cohort study
AU - Inghammar, Malin
AU - Svanström, Henrik
AU - Melbye, Mads
AU - Pasternak, Björn
AU - Hviid, Anders
PY - 2016/2/26
Y1 - 2016/2/26
N2 - Objective To evaluate if oral fluoroquinolone use is associated with an increased risk of serious arrhythmia. Design Bi-national cohort study, linking register data on filled prescriptions, cases of serious arrhythmia, and patient characteristics. Setting Denmark, 1997-2011; Sweden, 2006-13. Participants The study cohort was derived from a source population of all Danish and Swedish adults, aged 40 to 79 years. 909 656 courses of fluoroquinolone use (ciprofloxacin 82.6%, norfloxacin 12.1%, ofloxacin 3.2%, moxifloxacin 1.2%, and other fluoroquinolones 0.9%) and 909 656 courses of penicillin V use, matched 1:1 on propensity score, were included. Main outcom e measure The main outcome was risk of serious arrhythmia (fatal and non-fatal), comparing courses of fluoroquinolone use with courses of penicillin V use (an antibiotic with no pro-arrhythmic effect). The risk period of interest was current use, defined as days 0-7 of treatment. Subgroup analyses were conducted according to country, sex, age, underlying cardiovascular disease, concomitant use of drugs known to increase the risk of torsades de pointes, fluoroquinolone type, and levels of arrhythmia risk score. Results 144 cases of serious arrhythmia occurred during follow-up, 66 among current fluoroquinolone users (incidence rate 3.4 per 1000 person years) and 78 among current penicillin users (4.0 per 1000 person years); comparing oral fluoroquinolone treatment with penicillin V, the rate ratio was 0.85 (95% confidence interval 0.61 to 1.18). Compared with penicillin V, the absolute risk difference was -13 (95% confidence interval -35 to 16) cases of serious arrhythmia per 1 000 000 courses of fluoroquinolones. The risk of serious arrhythmia was not statistically significantly increased in any of the subgroups, including analyses by fluoroquinolone type. Conclusions Contrary to previous reports, oral fluoroquinolone treatment was not associated with an increased risk of serious arrhythmia in the general adult populations of Denmark and Sweden. Given the statistical power of the study, even small increases in relative and absolute risk could be ruled out. Since ciprofloxacin was the most commonly used fluoroquinolone in our study, we cannot exclude that intraclass differences influence the risk of serious arrhythmia associated with other less frequently used fluoroquinolones.
AB - Objective To evaluate if oral fluoroquinolone use is associated with an increased risk of serious arrhythmia. Design Bi-national cohort study, linking register data on filled prescriptions, cases of serious arrhythmia, and patient characteristics. Setting Denmark, 1997-2011; Sweden, 2006-13. Participants The study cohort was derived from a source population of all Danish and Swedish adults, aged 40 to 79 years. 909 656 courses of fluoroquinolone use (ciprofloxacin 82.6%, norfloxacin 12.1%, ofloxacin 3.2%, moxifloxacin 1.2%, and other fluoroquinolones 0.9%) and 909 656 courses of penicillin V use, matched 1:1 on propensity score, were included. Main outcom e measure The main outcome was risk of serious arrhythmia (fatal and non-fatal), comparing courses of fluoroquinolone use with courses of penicillin V use (an antibiotic with no pro-arrhythmic effect). The risk period of interest was current use, defined as days 0-7 of treatment. Subgroup analyses were conducted according to country, sex, age, underlying cardiovascular disease, concomitant use of drugs known to increase the risk of torsades de pointes, fluoroquinolone type, and levels of arrhythmia risk score. Results 144 cases of serious arrhythmia occurred during follow-up, 66 among current fluoroquinolone users (incidence rate 3.4 per 1000 person years) and 78 among current penicillin users (4.0 per 1000 person years); comparing oral fluoroquinolone treatment with penicillin V, the rate ratio was 0.85 (95% confidence interval 0.61 to 1.18). Compared with penicillin V, the absolute risk difference was -13 (95% confidence interval -35 to 16) cases of serious arrhythmia per 1 000 000 courses of fluoroquinolones. The risk of serious arrhythmia was not statistically significantly increased in any of the subgroups, including analyses by fluoroquinolone type. Conclusions Contrary to previous reports, oral fluoroquinolone treatment was not associated with an increased risk of serious arrhythmia in the general adult populations of Denmark and Sweden. Given the statistical power of the study, even small increases in relative and absolute risk could be ruled out. Since ciprofloxacin was the most commonly used fluoroquinolone in our study, we cannot exclude that intraclass differences influence the risk of serious arrhythmia associated with other less frequently used fluoroquinolones.
UR - http://www.scopus.com/inward/record.url?scp=84960099308&partnerID=8YFLogxK
U2 - 10.1136/bmj.i843
DO - 10.1136/bmj.i843
M3 - Journal article
C2 - 26920666
AN - SCOPUS:84960099308
VL - 352
JO - The BMJ
JF - The BMJ
SN - 0959-8146
M1 - i843
ER -
ID: 257835742